Envoy Medical, Inc. Annual Report - How They Did This Year

Hey there! Thinking about investing in Envoy Medical, Inc.? This guide gives you the lowdown on their performance. We'll use plain English to help you decide if they fit your portfolio. We'll cover their year, their business, and what to watch. This report focuses on their financial year ending December 31, 2025.

Here's what we'll explore:

1. What does this company do and how did they perform this year?
2. Financial performance - revenue, profit, growth metrics
3. Major wins and challenges this year
4. Financial health - cash, debt, liquidity
5. Key risks that could hurt the stock price
6. Competitive positioning
7. Leadership or strategy changes
8. Future outlook
9. Market trends or regulatory changes affecting them

Here's what we know about Envoy Medical, Inc. for the year ended December 31, 2025:

1. What does this company do and how did they perform this year? Envoy Medical, Inc. is a hearing health company. It creates innovative medical technologies for people with hearing loss. Their core idea uses the ear's natural anatomy to pick up sound. This avoids external microphones.

   They have two main products:

   • The Esteem FI-AMEI: This was their first product. It's a fully implanted active middle ear implant, approved by the FDA in 2010. It remains the only FDA-approved fully implanted active hearing implant available. However, it failed commercially. The government (CMS) classified it as a hearing aid, so insurance didn't cover it. Still, about 1,000 devices were implanted globally. This gave Envoy Medical over two decades of experience with its unique sensor technology.

   • The Acclaim CI: This fully implanted cochlear implant is still investigational (in development and testing). In late 2015, they shifted focus to this product. They leveraged the Esteem's sensor technology. Traditional cochlear implants have a large external part. The Acclaim CI, however, is completely inside the ear. It uses a special sensor to capture sound. This means no external parts to wear!

     How the Acclaim CI works (and what to expect): If approved, surgeons would implant the Acclaim CI. The procedure is expected to take 2.5 to 3 hours under general anesthesia. Patients would likely feel mild to moderate discomfort. They would need several days of rest afterward. A four-week waiting period allows the ear to heal before activation. The Acclaim CI's battery pack lasts 8-12 years. Doctors can replace it in a less invasive chest surgery, not the entire system.

   This year was big for them. They completed a "Business Combination" on March 16, 2023. This is a fancy term for a merger. The company you see now, Envoy Medical, Inc., was previously Anzu Special Acquisition Corp I. So, it's like a new company formed from two existing ones.

   Important Note: Envoy Medical cannot sell the Acclaim CI until it receives FDA approval. This is true despite all its development.

2. Financial performance - revenue, profit, growth metrics For the financial year ending December 31, 2025, Envoy Medical reported about $0.8 million in revenue. This came mostly from limited Esteem sales and some grant funding. This is a slight increase from $0.7 million in 2024. However, the company continues to lose a lot of money. They reported a loss of about $28.5 million for 2025. This follows a $25.1 million loss in 2024.

   As of December 31, 2025, the value of their publicly traded shares was small, around $12.7 million. This makes them a very small company in the stock market, often called a "micro-cap." They also had about 76.8 million Class A common shares outstanding as of March 20, 2026.

   The company states it is an "early-stage company with a history of losses." They have "generated limited revenue from product sales." They also warned they "may not be able to achieve profitability in the future." This means they haven't made a profit yet, and might not for a while. Also, they do not plan to pay cash payouts (dividends) on their Class A Common Stock. So, investors shouldn't expect regular cash from their shares anytime soon.

3. Major wins and challenges this year

   • Major Wins:
     • The biggest news is the completion of their Business Combination (merger) on March 16, 2023. This is a big step for any company. It reshaped their structure and future direction. It also let them access public markets for funding.
     • The Acclaim CI received Breakthrough Device Designation from the U.S. FDA in 2019. This special status could speed up the review process. However, it doesn't guarantee approval.
     • Their first product, the Esteem FI-AMEI, received FDA approval in 2010. This showed they could get a fully implanted device through regulatory hurdles.
   • Challenges/Things to Note:
     • Financial Statement Correction: The company corrected an error in its financial statements for this period. This fix mainly related to accounting for warrant obligations and certain ownership stakes after the merger. Investors should note this. It means past financial reports were not fully accurate. This can affect investor confidence and reporting reliability.
     • Material Weaknesses in Internal Controls: The company found "material weaknesses" in its financial reporting controls. This is serious. It means their systems for tracking financial information aren't robust enough. This could lead to inaccurate reports. It also affects investor confidence.
     • Esteem FI-AMEI Commercial Failure: The Esteem was FDA approved. Yet, it failed to gain commercial traction. This was mainly because CMS classified it as a hearing aid. This limited insurance coverage. It highlights a big hurdle for medical device companies.
     • Recent Financing: They issued various types of warrants. These include GAT Warrants, September 2025 Warrants, October 2025 Warrants, and Shortfall Warrants. Warrants are like options; they give holders the right to buy stock later. Issuing many warrants often means the company raised money. This can fund growth. However, it might also mean more shares are issued, reducing your ownership percentage if those warrants are used.

4. Financial health - cash, debt, liquidity As of December 31, 2025, Envoy Medical reported about $4.2 million in cash. This is a low cash balance. The company has significant ongoing research and development costs. It also has a substantial loss. They had about $16.5 million in total debt at the same date. The company also had a shortage of ready cash to cover immediate bills of about $10.1 million. This means they owed more short-term than they owned short-term.

   Their market value is quite small, around $12.7 million. This suggests they are a relatively young or small company. They might have less financial cushion than larger, more established businesses. The recent warrant issuance shows they are actively seeking funding.

   A big concern: their financial statements include a warning. It mentions "substantial doubt about our ability to continue as a going concern." This is a serious red flag. Auditors worry the company might not have enough money to stay in business long-term without more funding. This could make getting new financing very difficult. They also stated they may need to raise much more funding in the future. There's no guarantee they'll get it on good terms, or at all. The previously mentioned material weaknesses in financial reporting controls also cloud their financial health and reporting reliability.

5. Key risks that could hurt the stock price The company itself highlighted several important risks. These could impact its future and your investment. Pay close attention to them:

   • Early Stage & Profitability: They are an early-stage company. They have a history of losses and limited revenue. There's no guarantee they will ever make a profit.
   • Going Concern Doubt: There's "substantial doubt about our ability to continue as a going concern." This means their ability to stay in business is uncertain.
   • Need for More Funding & Dilution: They will likely need to raise more money. This funding might not be available. Or it could mean more shares are issued, reducing your ownership percentage.
   • Unpredictable Medical Device Industry: The medical device world constantly changes. Getting new products approved by regulators like the FDA is long, uncertain, and expensive. They might also need to change products to meet safety and effectiveness standards.
   • Acclaim CI Specific Risks: Their business heavily relies on the Acclaim CI. If it has design or manufacturing defects, or if clinical trials fail, or if doctors don't recommend it, this would severely harm their ability to make money.
     • FDA Approval Delays: The Acclaim CI has "Breakthrough Device" status. Still, if FDA approval is significantly delayed, competitors might release similar products first. This would hurt Envoy Medical's competitive edge.
   • Reimbursement Policy Changes: Government or insurance policies might change how much they pay for medical devices. This could hurt Envoy Medical's sales. It was a major issue for their Esteem product.
   • New Technologies: Breakthroughs like gene therapy or new medications could reduce the need for their hearing devices. This poses a big competitive threat.
   • Intense Competition: The medical device industry is competitive. Envoy Medical must keep innovating. They need to offer competitive products to succeed.
   • Supply Chain Issues: Problems getting key components or materials could slow production and sales. Disruptions in their manufacturing (they use third-party makers) could also cause delays.
   • Market Size Uncertainty: Their business plan relies on market assumptions. But the actual market size might be smaller than they estimate. They might not capture enough market share.
   • Reliance on Third Parties: They depend on third parties for clinical trials, data collection, and patient enrollment. This could lead to costs and delays beyond their control.
   • Internal Control Weaknesses: The material weaknesses in their financial reporting controls could lead to inaccurate financial statements. This would hurt investor confidence.
   • IT System Failure: A failure in their information technology systems could harm their business.
   • Leadership Dependence: They highly depend on key executive management team members. Losing these individuals could negatively impact their business plans.
   • Stock Price Volatility: Their stock and warrant prices have been and may remain extremely volatile. Big ups and downs are possible.
   • Legal and Regulatory Headaches: Lawsuits (including potential shareholder class-action suits) or new regulations could be costly and time-consuming.
   • Protecting Their Ideas: Losing their intellectual property rights (like patents) or failing to protect them could harm their competitive edge. They actively file patents and trademarks (as seen below). But the risk remains if they can't enforce or protect them.
   • Nasdaq Listing Risk: They might not keep their Nasdaq stock market listing. This could make it harder for investors to trade their stock.
   • Global Events: Big events like wars or terrorism could also impact their business.

6. Competitive positioning Envoy Medical operates in a very competitive medical device market. They aim to "disrupt the cochlear implant market" with their Acclaim CI. Three main established companies currently dominate this market. These are Cochlear Ltd., Advanced Bionics (owned by Sonova), and Med-El. Cochlear Ltd. is a giant here. It holds about 65% of the global market share. Its market value was around $12 billion USD as of December 31, 2025. Smaller regional players also exist, like Nurotron in China.

   Envoy Medical faces big challenges compared to these established companies:

   • Market Reach & Relationships: The big players have been around longer. They have deep relationships with audiologists, ENT doctors, and hearing centers. These medical professionals refer patients. They also have existing relationships with patients using their devices. Envoy Medical is newer to this market. It doesn't have these connections yet.
   • Financial & Operational Resources: Major competitors have much more money and operational power. This gives them a huge advantage. They can develop new technology and adapt to market changes faster.

   Envoy Medical's competitive edge comes from the Acclaim CI's unique fully implanted design. This offers several potential advantages over existing devices:

   • Increased daily usage: You can use it 24 hours a day, even at night for alarms.
   • Water-friendly: No need to remove it for showering, swimming, or rain.
   • Active lifestyle: It won't fall off during exercise or physical activities.
   • Lower maintenance: It has wireless charging. The battery lasts for days. There are no small components to handle.
   • No backup needed: It's implanted, so there's less risk of loss or damage. No expensive backup processors are needed.
   • Comfort with accessories: It doesn't interfere with helmets, hats, or headphones.
   • Reduced stigma: No externally worn parts could encourage earlier cochlear implant adoption.
   • Potential for Cost Reduction and Better Health Outcomes: Envoy believes a fully implanted device like the Acclaim CI could reduce overall cochlear implant costs. It cuts out expensive external parts that often need replacing. Making it easier to use (all-day hearing, no stigma) could also improve health outcomes. This happens by increasing implant use and encouraging earlier adoption. New scientific advancements, like gene therapy, also pose a risk. This means competition comes not just from other device makers, but from entirely different medical solutions.

   Envoy Medical actively secures intellectual property to protect its unique technology and brand. They hold various patents. These include a "Combination Implant System with Removable Earplug Sensor and Implanted Battery." Others cover a "Cochlear Implant System with Improved Input Signal-to-Noise Ratio" and a "Combination Hearing Aid and Cochlear Implant System." These patents protect their innovations. Some extend protection until 2043. They also have several registered trademarks. These include "Acclaim," "Envoy," "Envoy Medical," "Esteem," and "Invisible Hearing." Their renewal dates are between 2027 and 2033. They even have a pending trademark for "Nature's Microphone." This connects to their core idea of using the ear's natural anatomy. This strong intellectual property portfolio is key to staying competitive against larger players.

7. Leadership or strategy changes The biggest change was the Business Combination (merger), completed on March 16, 2023. This transformed the company's structure. It effectively became a new entity. This resulted from the merger of Anzu Special Acquisition Corp I and Legacy Envoy. Such events often bring new strategic directions. They can also mean changes in leadership or management focus.

   A key strategic shift occurred in late 2015. They moved their primary focus from the Esteem FI-AMEI. Instead, they developed the Acclaim CI, using existing sensor technology. This was a major pivot in their product development strategy. The company also stresses its high dependence on key executive management team members. Any changes there could be impactful.

8. Future outlook Envoy Medical clearly banks on the Acclaim CI. They expect it to be their main money-maker. It should also disrupt the existing cochlear implant market. They believe its fully implanted design offers big advantages. These could lead to more patient adoption and a better quality of life.

   To get the Acclaim CI to patients, Envoy plans to build strong relationships with audiologists. These professionals are crucial. They work in surgical centers, receiving training and support. They also work in the wider community. There, they identify and refer potential Acclaim CI patients. Envoy believes many audiologists don't fully know about cochlear implant technology. So, educating them is a big part of their strategy.

   Beyond the U.S., Envoy eyes international markets. They plan to seek the CE Mark (a European certification) for the Acclaim CI. This will happen soon after FDA approval. Afterward, they'll explore promising markets. These include Australia, Brazil, and parts of Asia. Getting approvals and reimbursement there will also take time and effort.

   Looking ahead, their research and development will continue. Recent patents show focus on improved signal-to-noise ratio and combination systems. They will improve the Acclaim CI's existing design, especially its quality and reliability. They also plan to develop robust software and user interfaces. These will serve both patients and medical professionals. The pending "Nature's Microphone" trademark hints at their continued focus on natural sound processing and unique branding.

   Interestingly, they also mention their first product, the Esteem FI-AMEI. It faced commercial challenges due to reimbursement issues. Yet, it could still be a "potentially viable product with reimbursement" for a niche hearing market. This suggests they might revisit its potential later. They may try different reimbursement strategies.

   However, the path forward is challenging. They must successfully navigate the FDA approval process for the Acclaim CI. Approval isn't guaranteed, despite its Breakthrough Device designation. Even if approved, they need to invest heavily. This includes patient advertising, educating doctors, training staff, and building distribution channels. They must also form strong relationships with physicians to gain market share. This can't even start until FDA approval. They also need to ensure doctors recommend the Acclaim CI. And insurance companies must provide adequate coverage and reimbursement. The company's ability to secure more funding and address its "going concern" doubts will be critical for its survival and future plans.

9. Market trends or regulatory changes affecting them As a medical device company, Envoy Medical is heavily influenced by:

   • The regulatory approval process for new devices. This can be slow and unpredictable. The Esteem FI-AMEI experience shows FDA approval alone doesn't guarantee commercial success. Favorable reimbursement policies are also needed.
   • Changes in reimbursement policies from governments (like CMS) and insurance companies. These directly impact how much they get paid for products. This was a major hurdle for their Esteem product.
   • Broader market trends in healthcare. This includes new technologies like gene therapy. These could change how hearing loss is treated.
   • General changes in laws and regulations that apply to businesses.
   • The company also notes that significant hearing loss links to increased anxiety, depression, social isolation, falls, and cognitive decline. This highlights the growing medical need their products aim to address.

   Understanding the Hearing Loss Market:

   • Prevalence: Hearing loss is widespread. It affects about 15% of all U.S. adults. For older adults, it's even more common. Nearly 25% of people aged 65-74 have disabling hearing loss. This rises to 50% for those 75 and older. The CDC and WHO recognize it as one of the most common global disabilities.
   • Economic Impact: Untreated or undertreated hearing loss costs about $750 billion worldwide each year.
   • Types of Hearing Loss:
     • Sensorineural (about 90% of cases): Inner ear problems, often from damaged "hearing hair cells." Common causes include aging, noise exposure, or certain medications.
     • Conductive (about 10% of cases): Mechanical or structural issues in the outer or middle ear. Examples include problems with the ear canal, eardrum, or tiny hearing bones. Malformations, infections, or wax buildup can cause it.
     • Mixed: A combination of both sensorineural and conductive issues.
   • Severity Levels: Hearing loss ranges from normal (0-20 dB) to profound (90+ dB). People with moderate to profound hearing loss (70-90 dB) often struggle to understand speech. This is true even with hearing aids. Those with profound loss are clinically "deaf."
   • Current Hearing Devices:
     • Personal Sound Amplification Devices (PSAPs): Simple devices that make sounds louder. They suit normal to mild hearing loss.
     • Hearing Aids: The most common type. They are always external, using a microphone and speaker. They come in over-the-counter (for mild-moderate) and prescription versions (for more significant loss). People typically try these first.
     • Active Middle Ear Implants: Devices like Envoy's Esteem. They are fully or partially implanted in the middle ear. They treat moderate to severe hearing loss.

   Evolution and Trends in Cochlear Implants:

   • Cochlear implants have come a long way since 1961. They began as basic single-electrode devices for environmental awareness. By the 1980s, they quickly evolved into multi-channel devices. These became the standard of care for adults with profound hearing loss.
   • Over recent decades, the focus improved speech understanding. This came through better electrodes and sound processing. Eligibility also expanded. It now includes children and people with different hearing loss levels.
   • More recently, the industry shifted focus. It moved from major hardware changes to improving appearance and usability. This means smaller external components and color options. It also includes connectivity features, more water resistance, and better reliability. However, clinical effectiveness seems to have "plateaued" recently.
   • Looking ahead, the next decade's trend will likely continue. It will focus on usability, connectivity, lifestyle integration, and miniaturization. The goal is to make cochlear implants more appealing and easier to live with.
   • Another major trend is loosening clinical eligibility requirements. More people are now eligible for cochlear implants. This includes those with "better" hearing levels (e.g., moderate loss in lower frequencies). It also includes those with "single-sided deafness" (SSD). Med El (2019) and Cochlear (2021) both received FDA approval for treating SSD.
   • Despite these advances and expanded eligibility, industry estimates are striking. Less than 10% of adults who could benefit from a cochlear implant actually get one. This leaves a massive untapped market of over 90% of eligible adults. This represents a significant opportunity for new technologies like Envoy's Acclaim CI.
   • A key market trend they address is the lack of awareness among many audiologists. Many don't fully understand cochlear implant technology and its benefits. Envoy plans to invest heavily in educating these professionals. They will also build relationships with them. Audiologists are crucial for identifying and referring patients who could benefit from devices like the Acclaim CI.